Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
Chazot
P L
PL
Institute of Pharmacy, Chemistry and Biomedical Sciences, University of Sunderland, Tyne and Wear, UK. paul.chazot@sunderland.ac.uk
Hann
V
V
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002490:Central Nervous System / Q000187:drug effects*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D003072:Cognition Disorders / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D017442:Histamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D018100:Receptors, Histamine H3 / Q000737:chemistry* / Q000187:drug effects / Q000648:ultrastructure; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D017442:Histamine Agonists; D018100:Receptors, Histamine H3